Tier 4 — mechanistic

The bioavailability of apigenin-7-glucoside is influenced by human intestinal microbiota in rats

Laura Hanske, Gunnar Loh, Silke Sczesny, Michael Blaut, Annett Braune
Journal of Nutrition 2009 139(6):1095-1102

Bibliography

PubMed
PMID 19403720
DOI
10.3945/jn.108.102814

Study snapshot

DesignIn vivo comparative animal pharmacokinetic study
ModelGerm-free and human-intestinal-microbiota-associated rats
Sample
InterventionOral apigenin-7-glucoside
Duration
EndpointsApigenin metabolite formation; Urinary and fecal excretion; Microbiota-dependent bioavailability

What the study showed, in plain terms

This animal study tested whether gut microbes alter the metabolism and bioavailability of an apigenin glycoside.

Key findings

Human-associated intestinal microbiota changed the breakdown and systemic availability of apigenin-7-glucoside, supporting a role for gut microbial metabolism in apigenin exposure.

What this study can and cannot tell us

The model used rats carrying human microbiota, not human participants. Results cannot quantify the effect in ordinary supplement users.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology